Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Moodys
Colorcon
Express Scripts
Merck

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR KISQALI


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Kisqali

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02035813 ↗ DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). Recruiting Prof. W. Janni Phase 2 2014-01-01 Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer (MBC). However, even if the prognostic value of CTCs in MBC is well understood, the role of both CTC prevalence and CTC phenotype in predicting treatment response needs further investigation. DETECT IV is a prospective, multicenter, open-label, phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). Additional research on CTC dynamics and characteristics will provide a better understanding of the prognostic and predictive value of CTCs and is one step into a more personalized therapy for MBC.
NCT02344472 ↗ Detect V / CHEVENDO (Chemo vs. Endo) Recruiting Celgene Corporation Phase 3 2015-09-01 Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
NCT02344472 ↗ Detect V / CHEVENDO (Chemo vs. Endo) Recruiting DETECT study group Phase 3 2015-09-01 Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
NCT02344472 ↗ Detect V / CHEVENDO (Chemo vs. Endo) Recruiting Eisai GmbH Phase 3 2015-09-01 Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
NCT02344472 ↗ Detect V / CHEVENDO (Chemo vs. Endo) Recruiting Novartis Pharmaceuticals Phase 3 2015-09-01 Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
NCT02344472 ↗ Detect V / CHEVENDO (Chemo vs. Endo) Recruiting Roche Pharma AG Phase 3 2015-09-01 Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Kisqali

Condition Name

Condition Name for Kisqali
Intervention Trials
Breast Cancer 4
Prognostic Stage IV Breast Cancer AJCC v8 3
HER2-Negative Breast Cancer 3
Metastatic Breast Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Kisqali
Intervention Trials
Breast Neoplasms 17
Neoplasms 6
Carcinoma 3
Brain Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Kisqali

Trials by Country

Trials by Country for Kisqali
Location Trials
United States 37
Germany 5
Spain 3
Netherlands 2
Portugal 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Kisqali
Location Trials
Texas 5
California 4
District of Columbia 3
Massachusetts 3
New York 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Kisqali

Clinical Trial Phase

Clinical Trial Phase for Kisqali
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 12
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Kisqali
Clinical Trial Phase Trials
Recruiting 10
Not yet recruiting 7
Active, not recruiting 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Kisqali

Sponsor Name

Sponsor Name for Kisqali
Sponsor Trials
Novartis 13
National Cancer Institute (NCI) 7
Novartis Pharmaceuticals 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Kisqali
Sponsor Trials
Industry 36
Other 32
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Express Scripts
Boehringer Ingelheim
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.